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Fast atom bombardment (FAB) mass spectrometry was used to identify a new small myotoxin from the venom of the prairie rattlesnake (Crotalus 
viridis viridis), FAB mass spectrometry and Edman degradation were used to characterize its structure. This toxin is similar to myotoxin I from 
C. v. concolor, except hat it possesses an additional C-terminal asparaginyl-alanine. At 45 residues it is the longest known myotoxin a homolog. 
A myotoxin of 43 residues, identical to myotoxin I from C. v. concolor, was also found. To date no other species has been shown to produce 
more than one length of myotoxin. The present paper documents 42-, 43-, and 45-residue myotoxins from the venom of a single animal. 
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1. INTRODUCTION 
The small myotoxins are a unique class of  basic 
polypept ides from ratt lesnake venQms. They consist of  
42-43 residues, have high isoelectric points,  and cause 
severe muscle necrosis by a non-enzymat ic  mechanism. 
In contrast  to myotoxic  phosphol ipases,  the small 
myotox ins  act extremely rapid ly and serve two pr imary  
biological  functions: to l imit the fl ight o f  prey by caus- 
ing nearly instantaneous paralysis of  the hind l imbs, 
and to promote  rapid death by paralysis o f  the 
d iaphragm.  Small  myotoxins hare essential ly no struc- 
tural  attr ibutes with myotoxic  phosphol ipases which are 
more  ubiquitous among crotal ine venoms, and which 
presumably  disrupt membranes by hydrolyz ing sar- 
co lemma phosphol ip ids.  
The first small myotox in  to be discovered was 
crotamine,  a 42-residue polypept ide (pI  10.3) f rom the 
venom of  Crotalus durissus terrificus [1,2]. Its pr imary  
structure was determined 25 years later by Laure [3]. 
Several crotamine homologs have since been reported,  
including myotox in  a f rom the venom of C. viridis 
viridis [4,5], pept ide C f rom the venom of  C. v. helleri 
[6], and myotoxins I and II f rom the venom of  C. v. 
concolor [7,8]. Unl ike crotamine and myotox in  a, pep- 
t ide C and the two concolor myotoxins both consist of  
43 residues, rather than 42. The dif ference results f rom 
a C-terminal  valy l -asparagine in place of  the usual 
glycine. Another  myotox in  called Toxin E has been se- 
quenced f rom the venom of  C. h. horridus. It contains 
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42 residues and is nearly identical in pr imary  structure 
to crotamine and myotox in  a (C.R. Green and J .W.  
Fox,  personal  communicat ion) .  Most  recently, a possi- 
ble dimeric myotoxin has been reported f rom C. 
adamanteus venom [9]. 
The present communicat ion reports the discovery of  
a new small myotox in  f rom the venom of  the prair ie rat- 
t lesnake (Crotalus viridis viridis). This myotox in  was 
detected by fast a tom bombardment  (FAB) mass spec- 
t rometry  [10,11] and sequenced by a combinat ion of  
FAB mass spectrometry and automated Edman 
degradat ion.  
2. MATERIALS  AND METHODS 
2.1. Venom extraction and chromatography 
An adult (> 1 month) male prairie rattlesnake (Crotalus viridis 
viridis) was captured by SDA, 20 miles east of Meeker, Rio Blanco 
County, CO, at the eastern and elevational limits for the species. 
Venom was extracted manually at 2-3 week intervals and kept frozen 
at -20°C until use. Crude venom was diluted with 100 mM acetic 
acid/NaOH (pH 4.0), centrifuged at 10 000 rpm for 10 min to remove 
insoluble material, and fractionated on a 2.5 x 95 cm column of 
Sephacryl S-200 HR (Pharmacia-LKB) equilibrated in the same buf- 
fer. Fraction 5 was subfractionated on a 0.5 x 5 cm Mono S HR 
(Pharmacia-LKB) column equilibrated in 50 mM formic 
acid/NI-hOH (pH 4.0). Buffer B was identical except that it contained 
2 M NaCI. Further purification was achieved by passing the material 
from Mono S column over a 0.5 × 5 cm PepRPC HR (Pharmacia- 
LKB) column equilibrated in 250 mM formic acid/NH4OH (pH 4.0). 
Buffer B was identical except hat it contained 60°70 acetonitrile. 
2.2. Cyanogen bromide cleavage 
Cleavage with cyanogen bromide was achieved by adding 50/~g 
CNBr (Sigma) to 100/~l of 0.1% trifluoroacetic a id containing 10 #g 
of native myotoxin. After 12 h at room temperature in the dark, the 
reaction was stopped by the addition of two volumes of distilled 
water. 
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2.3. Fractionation of CNBr peptides 
Peptide mixtures were fractionated by HPLC on an RP-300 
aquapore reverse phase column (Cs, 300 A, 2.1 × 100 mm, Applied 
Biosystems) using a Brownleee Microgradient HPLC syringe pump 
equipped with a Rheodyne 7125 injector. Column effluent was 
monitored at 214 nm using a Kratos 783 UV detector and fractions 
were collected by hand. 
2.4. Mass spectrometry 
Samples were analyzed on a JEOL JMS-HXI10HF/HXll0HF 
tandem double-focusing mass pectrometer, using MS-1 only. The in- 
strument was operated at 10 kV accelerating voltage with resolution 
of 1 "500 and the mass axis was calibrated with cesium iodide with an 
accurary of + 0.3 Da. Sample (1 /~1) was mixed with 1 #1 of m- 
nitrobenzyl alcohol, on a gold-plated stainless teel FAB probe tip, 
and ions were formed by FAB using 10-20 keV Cs +. Data were ac- 
quired as raw profiles using the ACM program of the JEOL DA-5000 
data system. Masses are given as the chemical average mass of the 
peak centroid. 
2.5. Protein sequencing 
Automated Edman degradation was performed with an Applied 
Biosystems 470A gas phase sequencer quipped with a 120A PTH on- 
line amino acid analyzer. Phenylthiodydantoin-amino acidpeaks 
were integrated with a Nelson Analytical model 2600 data system and 
sequence data were interpreted on a VAX 8650 according to the 
method of Henzel et al. [11]. 
3. RESULTS AND DISCUSSION 
3.1. Chromatography 
Fract ionat ion  of  crude venom over Sephacryl  S-200 
HR resulted in 7 fractions (Fig. 1). Fract ion 5 contained 
myotox in  a and the new myotox in  with relatively few 
contaminants .  When subfact ionated over Mono S at 
pH 4.0, 3 fractions resulted. Contaminat ing mater ia l  
f rom S-200 fractions 4 and 6 eluted in a heterogeneous 
peak early in the gradient (Fig. 2). The major ,  
somewhat  assymetric second peak contained myotox in  
a, and the new myotox in  eluted last. 
Reverse phase chromatography  of Mono S fract ion 3 
yielded 4 fractions (Fig. 3). Fract ions 1 and 2 both con- 
sisted of  myotoxin a o f  identical mass, while fractions 
3 and 4 both contained the new myotoxin,  also of  iden- 
t ical mass. When fract ion 3 was passed back over 
PepPRC under identical condit ions,  contaminat ing 
myotox in  a was el iminated, but large amounts  of  frac- 
t ion 4 were generated f rom fract ion 3 (not shown). This 
suggests that fractions 3 and 4 may represent dif ferent 
charge or conformat iona l  states of  the same pr imary  
structure. G lutamate  residues may be impl icated since 
the peak-doubl ing phenomenon is not seen when 
myotox ins  are f ract ionated at pH 5.5. 
3.2. Amino acid sequence analysis 
Analys is  of  PepRPC fractions 1 and 2 (Fig. 3) by 
FAB mass spectrometry af forded mass spectra (not 
shown) containing abundant  protonated molecular  ions 
(MH +) at m/z  4824.0 (Table I). The predicted MH ÷ 
for authentic myotox in  a is 4822.8, thus, PepRPC frac- 
t ions 1 and 2 were identif ied as myotox in  a. Analysis  of  
PepRPC fract ions 3 and 4 af forded the mass spectrum 
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Fig. 1. Fractionation f crude prairie rattlesnake v nom over a 2.5 × 
95 cm column of Sephacryl S-200 HR. Myotoxin a and the new 
myotoxin eluted in fraction 5. 
shown in Fig. 4. The major  peak was at m/z  5240.0, 185 
Da higher than the predicted mass of  any known 
myotox in .  
Amino  terminal  sequence analysis using automated 
Edman degradat ion was per formed on an al iquot of  
PepRPC fract ion 3, identi fying the first 29 residues 
(Table II). The derived amino terminal  sequence was 
identical  to those of  C. v. concolor myotoxins I and II  
[8]. Heterogeneity at posi t ion 8, with similar amounts  
o f  both  glycine and glutamic acid, was also reported in 
the C. v. concolor myotoxins [8]. 
The carboxyl  terminus of  the new myotoxin was se- 
quenced after CNBr  cleavage and disulf ide bond reduc- 
t ion. The resulting peptides were separated by reverse 
phase HPLC.  Analysis of  CNBr  fractions 1 and 2 by 
FAB mass spectrometry af forded two mass spectra with 
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Fig. 2. Subfractionation f Sephacryl S-200 HR fraction 5 over a 0.5 
x 5 cm Mono S HR column. Fraction 1 contained contaminating 
material from S-200 fractions 4and 6. Fraction 2contained myotoxin 
a while the new myotoxin eluted in fraction 3. 
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Fig. 3. Subfractionation f Mono S fraction 3 over a 0.5 x 5 cm 
PepRPC HR column. Fractions 1 and 2 both contained myotoxin a
of identical mass (4926 Da). Fractions 3 and 4 both contained the 
novel myotoxin (5250 Da). 
abundant MH + ions at m/z  2026.8 and 3189.2, respec- 
tively (Table I). The combined molecular masses 
observed for these two peptides um to the observed 
mass of the novel myotoxin, 5040.2 [2026.8 (CNBr-1) 
+ 3189.2 (CNBr-2) -101 (homoserine lactone) + 
131.1 (methionine) -6  (minus 6 protons to form 3 
disulfides) = 5040.1]. The mass of CNBr fraction 2 
(3189.2), corresponds to the amino acid sequence of 
residues 1-28. CNBr fraction 1 was sequenced directly 
by automated Edman degradation and the resulting 
amino acid sequence is shown in Table II. This sequence 
corresponds toresidues 29-45 and the observed mass of 
this peptide (2026.8) is in close agreement with the 
predicted mass (2027.4). Thus the novel myotoxin ends 
in asparaginyl-alanine a d has a total of 45 amino acid 
residues, the longest small myotoxin presently known. 
Minor peaks were observed in the mass spectrum of 
PepRPC fraction 3 (Fig. 3). Peaks observed at m/z  
Table lI 
Sequence analysis of PepRPC fraction 3 and CNBr fraction I. 
PepRPC fraction 3 CNBr fraction 1 
Cycle Amino acid Yield (pmol) Amino acid Yield (pmol) 
1 Y 20.6 
2 K 9.0 
3 R 6.2 
4 C (a) 
5 H 4.9 
6 K 5.9 
7 K 8.2 
8 E,G 5.6,4.0 
9 G 7.3 
10 H 3.9 
11 C (a) 
12 F 5.4 
13 P 5.4 
14 K 2.0 
15 T 2.1 
16 V 2.6 
17 I 1.9 
18 C (a) 
19 L 1.7 
20 P 2.2 
21 P 3.5 
22 S 2.7 
23 S 1.6 
24 D 0.6 
25 F 0.6 
26 G 0.2 
27 K 0.3 
28 M 0.4 
29 D 0.2 
D 124 
c (a) 
R 72.1 
W 15.6 
K 58.9 
W 15.9 
K 66.3 
c (a) 
c (a) 
K 30.0 
K 39.8 
G 20.6 
S 10.8 
V 11.6 
N 8.7 
N 12.4 
A 2.1 
(a) Cysteine was identified by the presence of a dehydroalanine p ak 
and the absence of a serine peak during the cycle. 
5168.9 and 5055.4 correspond to myotoxin sequences 3 
and 4, respectively (Table I). Sequence 4 is identical to 
myotoxin I from C. v. concolor [8]; thus, the venom of 
this single C. v. viridis contains at least 3 different small 
myotoxins, based on length. At present no other species 
has been shown to possess more than one type. While 
the 43- and 45-residue myotoxins may simply result 
from differential post-template processing of the same 
Table I 
Summary of mass spectrometric data obtained on PepRPC fractions 1 through 4 and after cyanogen bromide cleavage of PepRPC fraction 3. 
Sequence Fraction MH + MH ÷ 
calculated observed 
1. YKQCHKKGGHCFPKEKICIPPSSDLGKMDCRWKWKCCKKGSG 
2. YKRCHKKEGHCFPKTVICLPPSSDFGKMDCRWKWKCCKKGSVNNA 
3. YKRCHKKGGHCFPKTVICLPPSSDFGKMDCRWKWKCCKKGSVNNA 
4. YKRCHKKEGHCFPKTVICLPPSSDFGKMDCRWKWKCCKKGSVN 
5. YKRCHKKEGHCFPKTVICLPPSSDFGK(hS) 
6. DCRWKWKCCKKGSVNNA 
PepRPC- 1 4822.8 4824.0 
PepRPC-2 
PepRPC-3 5241.2 5240.0 
PepRPC-4 
PepRPC-3 5169.2 5168.9 
PepRPC-4 
PepRPC-3 5056.2 5055.4 
PepRPC-4 
CNBr-2 3188.6 3189.2 
CNBr- 1 2027.4 2026.8 
Masses are reported as the chemical average of the peak centroid. All observed masses are accurate to within 0.03%. 
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Fig. 4. FAB mass spectrum of PepRPC fraction 3. 
A. 
terr i f icus 
vindls - 1 
5 10 15 20 25 30 35 40 
Y K Q C H K K G G H C F  PKE  K I C LP  P SSD F G K M D C R W R W K C C K K G S G  
Y K Q C H K K G G H C F P K E K I C I P P SSD L G K M D C R W K W K C C K K G S  G 
B. 
hel ler i  
conco lor  
conco lor  
I 5 10 15 20 25 30 35 40 
Y K R C H K K G G H C F  P K T V  I C LP  P S S D F G K M D C R W K W K C C K K G S V N  
Y K R C H K K E G H C F  P K T V  I C LPP  S S D F G  K M D C R W K W K C C K K G S V N  
Y K R C H K K G G H C F  P K E K  I CTP  P S S D F G K M D C R W K W K C C K K G S V N  
C.  
adamanteus  Y K R C H K K G G H C F P  KTV I C LP  P SSD F G K M D C R W R W K C C K K G S V N N  ? 
D. 
wndis  - 2 
wridis - 3 
vlridis - 4 
Y K R C H K K E G H C F P K T V I C L P P S S D F G K M D C R W K W K C C K K G S V N N A  
Y K R C H K K G G H C F P K T V I C L P P S S D F G K M D C R W K W K C C K K G S V N N A  
Y K R C H K K E G H C F P K T V I C L P P S S D F G K M D C R W K W K C C K K G S V N  
Fig. 5. Amino acid sequences of small myotoxins. The new myotoxin is most similar to myotoxin I from C. v. concolor  rather than to myotoxin 
a from C. v. viridis. Literature references are as follows: (A) 42-residue myotoxins, C. d. terrif icus [3]; C. v. viridis [5]; (B) 43-residue myotoxins, 
C. v. helleri [6]; C. v. concolor  [8]; (C) Dimeric myotoxin, C. adamanteus [9]. (D) New myotoxins from C. v. viridis venom, present study. 
gene, differential processing cannot account for the 
presence of myotoxin a. The present work lends addi- 
tional support to the suggestion by Aird et al. [13] that 
the myotoxin gene has been duplicated in C. v. viridis. 
3.3. Nomenclatural  suggestions 
Seven different names for small myotoxins are cur- 
rently established in the toxinological iterature, even 
though no names have been assigned to the increasing 
number of structural variants of myotoxin a [13] and 
crotamine [14]. It seems unwise to assign different 
names to simple amino acid substitutions in the same 
primary structure. However, it may be useful to 
distinguish between the various lengths of myotoxin, 
especially in C. v. viridis, where several sizes occur. It is 
also unlikely that C. v. viridis will remain an isolated 
case. It would probably be best to refer to these 
molecules by length (42-residue myotoxins, 45-residue 
myotoxins, etc). This would be more descriptive than 
referring to them as Class 1, 2, 3 or Type A, B, C, etc. 
We strongly recommend dispensing with trivial names 
such as crotamine, Peptide C, Toxin E, etc., which in- 
dicate neither function nor homology within the group. 
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